Kaposiform Hemangioendothelioma Clinical Trial
Official title:
Guided Discontinuation Versus Maintenance Treatment of Sirolimus in Pediatric Patients With Kaposiform Hemangioendothelioma: a Randomized Controlled Trial
This randomized controlled trial aims to compare guided discontinuation with maintenance treatment of sirolimus in pediatric patients with KHE.
Kaposiform Hemangioendothelioma (KHE) is a rare vascular tumor that occurs in infants and children. KHE is characterized by sheets of spindle cells with an infiltrative pattern in the dermis, subcutaneous fat, and muscle. It is locally aggressive and can cause Kasabach-Merritt phenomenon, a serious life-threatening coagulopathy characterized by profound thrombocytopenia and hypofibrinogenemia. Sirolimus, one of the mTOR inhibitors, has become a new and very effective treatment, which is especially reliable for KHE with KMP and has acceptable side effects. However, there is yet no strong evidence on the best practice of treatment length of sirolimus. This randomized controlled trial aims to compare guided discontinuation with maintenance treatment in pediatric patients with KHE in order to provide a basis for the optimal treatment duration of sirolimus, as well as the clinical characteristics of pediatric patients who can safely reduce the dose till withdrawal. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04921722 -
Percutaneous Administration of Sirolimus in the Treatment of Superficial Complicated Vascular Anomalies
|
Phase 4 | |
Completed |
NCT04077515 -
Safety and Efficacy of Low-dose Sirolimus to Kaposiform Hemangioendothelioma
|
Phase 4 | |
Recruiting |
NCT05351216 -
The Effect of Sirolimus on Immunizations During the Treatment of Kaposiform Hemangioendothelioma
|
||
Completed |
NCT03188068 -
Sirolimus Versus Sirolimus Plus Prednisolone for Kaposiform Hemangioendothelioma
|
Phase 2 | |
Completed |
NCT04775173 -
Efficacy and Safety of Different Concentrations of Sirolimus in the Treatment of Kaposiform Hemangioendothelioma.
|
Phase 2 | |
Recruiting |
NCT03001180 -
Identification of Biomarkers for Patients With Vascular Anomalies
|